Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 1;26(6):303-311.
doi: 10.2459/JCM.0000000000001735. Epub 2025 May 13.

Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?

Paolo Ossola  1 , Claudio Ciampi  1 , Andrea Cesari  2 , Luca Villanova  2 , Niccolò Grieco  3 , Giovanna Viola  2 , Alice Sacco  2 , Leonardo De Luca  4 , Fabrizio Oliva  2
Affiliations
Review

Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?

Paolo Ossola et al. J Cardiovasc Med (Hagerstown). .

Abstract

Factor XI (FXI) is one of the components of the coagulation cascade, connecting its intrinsic and common pathway. FXI inhibitors have emerged in these few years as interesting therapeutic drugs, with potential advantages over standard anticoagulants in terms of lowering thrombotic risk and limiting bleeding consequences. Better knowledge of the underlying processes of thrombosis led to the design of several clinical trials based on the inhibition of this factor. The discovery of molecules, antibodies, and antisense oligonucleotides capable of binding to this factor is paving the way for new anticoagulation strategies, which will be analyzed in this review.

Keywords: FXI inhibitors; anticoagulation; thrombosis.

PubMed Disclaimer

References

    1. Isabelle C, Van Gelder, Michiel Rienstra, Karina V Bunting, et al. ESC Scientific Document Group, 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024; 45:3314–3414.
    1. Bejjani A, Khairani CD, Assi A, et al. When direct oral anticoagulants should not be standard treatment: JACC State-of-the-Art Review. J Am Coll Cardiol 2024; 83:444–465.
    1. Curcio Antonio, Anselmino Matteo, Di Biase Luigi, et al. The gray areas of oral anticoagulation for prevention of thromboembolic events in atrial fibrillation patients. J Cardiovasc Med 2023; 24: (Suppl 2): e97–e105.
    1. Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation: meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116:754–763.
    1. Camm AJ, Amarenco P, Haas S, et al. XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37:1145–1153.

LinkOut - more resources